Fabry disease: Perspectives of urinary proteomics

Journal of Nephrology

Volumn 23, Issue SUPPL.16, 2010, Pages

  Cuccurullo, Manuela ^a   Beneduci, Amerigo ^b   Anand, Santosh ^c   Mignani, Renzo ^d   Cianciaruso, Bruno ^e   Bachi, Angela ^c   Capasso, Giovambattista ^d  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF CALABRIA   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d INFERMI HOSPITAL   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Biomarker; Fabry disease; Proteomics; Urine

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; ENZYME REPLACEMENT; FABRY DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; METHODOLOGY; PROTEOMICS; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; URINE;

BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; HUMANS; MALE; PROTEOMICS; TANDEM MASS SPECTROMETRY;

EID: 79952277670     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Anderson WA. A case of angiokeratoma. Br J Dermatol. 1898;18:113-117.
2. Fabry J. Ein Betrag zur Kenntnis der Ppurpura hammarrhagica nodularis. Arch Dermatol Syphilol. 1898;43:187-200.
3. Brady RO, Gal AE, Bradley RM, et al. Enzymatic defect in Fabry's disease: ceramidetrihexosidase deficiency. N Engl J Med. 1967;276:1163-1167.
4. Kint JA. Fabry's disease: alpha-galactosidase deficiency. Science. 1970;167:1268-1269.
5. Peters FP, Vermeulen A, Kho TL. Anderson-Fabry's disease: alpha-galactosidase deficiency. Lancet. 2001;357:138-140.
6. Zarate YA, Hopkin RJ. Fabry's disease. Lancet. 2008;372:1427-1435.
7. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38:750-760.
8. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38:769-775.
9. Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24:2102-2111.
10. Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146:77-86.
11. Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285:2743-2749.
12. Eng CM, Banikazemi M, Gordon RE, et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet. 2001;68:711-722.
13. Schiffmann R, Askari H, Timmons M, et al. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol. 2007;18:1576-1583.
14. Desnick RJ, Allen KY, Desnick SJ, et al. Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes: alphagalactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med. 1973;81:157-171.
15. Chamoles NA, Blanco M, Gaggioli D. Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta. 2001;308:195-196.
16. Kitagawa T, Ishige N, Suzuki K, et al. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry. Mol Genet Metab. 2005;85:196-202.
17. Whitfield PD, Calvin J, Hogg S, et al. Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide. J Inherit Metab Dis. 2005;28:21-33.
18. Kitagawa T, Suzuki K, Ishige N, et al. Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes. Pediatr Nephrol. 2008;23:1461-1471.
19. Young E, Mills K, Morris P, et al. Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr Suppl. 2005;94:51-54 [discussion: 37-38].
20. Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A. 2008;105:2812-2817.
21. Auray-Blais C, Cyr D, Ntwari A, et al. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol Genet Metab. 2008;93:331-340.
22. Barr C, Clarke JT, Ntwari A, Drouin R, Auray-Blais C. Fabry disease urinary globotriaosylceramide/creatinine biomarker evaluation by liquid chromatography-tandem mass spectrometry in healthy infants from birth to 6 months. Mol Genet Metab. 2009;97:278-283.
23. Tahir H, Jackson LL, Warnock DG. Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase- beta. J Am Soc Nephrol. 2007;18:2609-2617.
24. Hara M, Yanagihara T, Kihara I. Urinary podocytes in primary focal segmental glomerulosclerosis. Nephron. 2001;89:342-347.
25. Garovic VD, Wagner SJ, Turner ST, et al. Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol. 2007;196:320-327.
26. DeGraba T, Azhar S, Dignat-George F, et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol. 2000;47:229-233.
27. Barbey F, Brakch N, Linhart A, et al. Increased carotid intimamedia thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease. Acta Paediatr Suppl. 2006;95:63-68.
28. Decramer S, Gonzalez de Peredo A, Breuil B, et al. Urine in clinical proteomics. Mol Cell Proteomics. 2008;7:1850-1862.
29. Davis MT, Spahr CS, McGinley MD, et al. Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry: Part II: limitations of complex mixture analyses. Proteomics. 2001;1:108-117.
30. Pang JX, Ginanni N, Dongre AR, Hefta SA, Opitek GJ. Biomarker discovery in urine by proteomics. J Proteome Res. 2002;1:161-169.
31. Thongboonkerd V, McLeish KR, Arthur JM, Klein JB. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int. 2002;62:1461-1469.
32. Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A. 2004;101:13368-13373.
33. Castagna A, Cecconi D, Sennels L, et al. Exploring the hidden human urinary proteome via ligand library beads. J Proteome Res. 2005;4:1917-1930.
34. Jurgens M, Appel A, Heine G, et al. Towards characterization of the human urinary peptidome. Comb Chem High Throughput Screen. 2005;8:757-765.
35. Magagnotti C, Fermo I, Carletti RM, Ferrari M, Bachi A. Comparison of different depletion strategies for improving resolution of the human urine proteome. Clin Chem Lab Med. 2010;48:531-535.
36. Ong SE, Blagoev B, Kratchmarova I, et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics. 2002;1:376-386.
37. Gygi SP, Rist B, Gerber SA, et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol. 1999;17:994-999.
38. Yao X, Freas A, Ramirez J, Demirev PA, Fenselau C. Proteolytic 18O labeling for comparative proteomics: model studies with two serotypes of adenovirus. Anal Chem. 2001;73:2836-2842.
39. Ross PL, Huang YN, Marchese JN, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using aminereactive isobaric tagging reagents. Mol Cell Proteomics. 2004;3:1154-1169.
40. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Chem. 1976;72:248-254.
41. Matafora V, D'Amato A, Mori S, Blasi F, Bachi A. Proteomics analysis of nucleolar SUMO-1 target proteins upon proteasome inhibition. Mol Cell Proteomics. 2009;8:2243-2255.
42. Stahl S, Fung E, Adams C, et al. Proteomics and pathway analysis identifies JNK signaling as critical for high linear energy transfer radiation-induced apoptosis in non-small lung cancer cells. Mol Cell Proteomics. 2009;8:1117-1129.
43. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem. 1975;250:4007-4021.
44. Candiano G, Musante L, Bruschi M, et al. Repetitive fragmentation products of albumin and alpha1-antitrypsin in glomerular diseases associated with nephrotic syndrome. J Am Soc Nephrol. 2006;17:3139-3148.
45. Mehta A, Beck M, Elliott P, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet. 2009;374:1986-1996.
46. Schiffmann R, Waldek S, Benigni A, Auray-Blais C. Biomarkers of Fabry disease nephropathy. Clin J Am Soc Nephrol. 2010;5:360-364.
47. Moore DF, Krokhin OV, Beavis RC, et al. Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities. Proc Natl Acad Sci U S A. 2007;104:2873-2878.
48. Vylet'al P, Hulkova H, Zivna M, et al. Abnormal expression and processing of uromodulin in Fabry disease reflects tubular cell storage alteration and is reversible by enzyme replacement therapy. J Inherit Metab Dis. 2008;31:508-517.